whitepaper
Whitepaper: Remdesivir: The technologies behind the discovery
Remdesivir is being prescribed under FDA emergency use authorisation as a treatment for patients with COVID-19.
List view / Grid view
Biopharmaceuticals
video
Webinar: Novel flow cytometry ACE-2 blocking assay
This webinar from Bio-Techne demonstrates how to use a novel in vitro flow cytometry-based assay to monitor SARS-CoV-2 binding to ACE-2.
whitepaper
Whitepaper: Virus vaccine research – accelerated workflows
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
whitepaper
Whitepaper: Ensure drug development success
Getting a drug product to market can be a challenging process with lots to consider, but Recipharm’s team of experts is here to support you.
news
Identification of novel biosynthetic pathways in lichens could lead to new therapeutics
Scientists have identified a new family of biosynthetic genes in lichens with unknown functions, which could produce new molecules for the pharmaceutical industry.
article
Combining deep computational learning and synthetic biology
Dr Diogo Camacho from the Wyss Institute at Harvard discusses new research into using machine learning algorithms to analyse RNA sequences and reveal potential drug targets.
article
Advancing CHO cell line engineering with CRISPR
Chinese hamster ovary (CHO) cell lines are a firm favourite with biologics companies because of the extensive developmental work undertaken in recent decades. In this article, Junrui Li divulges how CRISPR technology is now being employed to further enhance productivity.
article
Biosynthetic polysaccharide-based drugs and nutraceuticals from non-animal sources
Glycosaminoglycans (GAGs) are a class of naturally occurring polysaccharides that play vital roles in cellular functions. GAGs (eg, hyaluronic acid, heparosan, chondroitin, chondroitin sulfate, heparan sulfate and heparin) have also been utilised in biopharmaceutical and nutraceutical industries. Animal-sourced GAGs can contain process impurities and contaminants, which may result in adverse…
article
A rational approach to discover and precision-engineer new biologic drugs
When it comes to developing antibody drugs, Dr Jerome Boyd-Kirkup and his team are not sticking to the classical playbook. Here, he explains how they use systems biology and immuno-engineering to remove the element of luck from biologic drug discovery and development.
whitepaper
Product hub: Vi-CELL BLU cell viability/counting analyser
The Vi-CELL BLU automates the widely accepted trypan blue dye exclusion method for cell viability that has historically been performed with a light microscope, pipette, and a hemacytometer.
article
Upstream Bioprocessing In-Depth Focus 2020
In the upstream bioprocessing in-depth focus experts reveal how CRISPR is being leveraged to enhance productivity in cell line development and why industry is focusing on producing animal-component free glycosaminoglycans.
news
Cell line development services market to grow at 13.3 percent
Reports suggest the market growth is driven by advances in biotechnology and its applications, as well as COVID-19 research.
news
New bioprocess generates haematopoietic stem and progenitor cells
A new single-use, closed-system upstream bioprocess has been developed which enables the production of large number of haematopoietic stem cells and progenitor cells.
video
On-demand webinar: Complete workflow solution from gene-to-protein
23 October 2020 | By
Our full gene-to-protein workflow can support your research for rapid protein production early during drug development so you can minimize changes from R&D to bioproduction.
news
Platform for hit-to-lead identification of antibacterial lysins developed
A group of scientists has created a novel high-throughput hit-to-lead development platform to identify engineered antibacterial lysins.
